Baraliakos, X.
Sewerin, P.
de Miguel, E.
Pournara, E.
Kleinmond, C.
Shekhawat, A.
Jentzsch, C.
Wiedon, A.
Behrens, F.
,
Article History
Received: 17 February 2022
Accepted: 3 May 2022
First Online: 16 May 2022
Declarations
:
: The study was carried out in accordance with the principles of the Declaration of Helsinki, International Conference of Harmonisation Good Clinical Practice guidelines, and all applicable laws and regulations, with written informed consent obtained from all enrolled patients.
: Not applicable
: X Baraliakos received grant/research support from AbbVie and Novartis; consulting fees from AbbVie, BMS, Celgene, Chugai, Galapagos, Gilead, MSD, Novartis, Pfizer, and UCB; and on the speakers bureau of AbbVie, BMS, Celgene, Chugai, MSD, Novartis, Pfizer, and UCB. P Sewerin received grant/research support from AbbVie, Celgene, Chugai, Janssen-Cilag, Lilly, Novartis, Pfizer, and UCB; was a consultant for AbbVie, Biogen, BMS, Celgene, Chugai, Hexal, Janssen-Cilag, Lilly, Novartis, Pfizer, Roche, Sanofi-Genzyme, Swedish Orphan Biovitrum, and UCB; and on the speaker’s bureau of AbbVie, Biogen, BMS, Celgene, Chugai, Hexal, Janssen-Cilag, Lilly, Novartis, Pfizer, Roche, Sanofi-Genzyme, Swedish Orphan Biovitrum, and UCB. E De Miguel received grant/research support from AbbVie, Novartis, and Pfizer; was a consultant for AbbVie, Novartis, and Pfizer; and on the speakers bureau of AbbVie, BMS, MSD, Novartis, Pfizer, UCB, and Roche. E Pournara, C Kleinmond, A Shekhawat, C Jentzsch and A Wiedon are employees of Novartis and may own Novartis stock. F Behrens received grant/research support from AbbVie, Pfizer, Roche, Chugai, Janssen, and Novartis; consultancies/speakers fee from AbbVie, Pfizer, Roche, Chugai, UCB, BMS, Celgene, MSD, Novartis, Biotest, Janssen, Sanofi, Genzyme, Lilly, Boehringer, and Galapagos.